ArticleTranslational lung cancer research2020
Article in Translational lung cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Obstructive sleep apnea and lung cancer: molecular underpinnings and clinical translational prospects.Frontiers in cell and developmental biology · 2026Review
- Molecular Imaging for Lung Cancer: Exploring Small Molecules, Peptides, and Beyond in Radiolabeled Diagnostics.Pharmaceutics · 2024Review
- The lung cancers: staging and response, CT,The British journal of radiology · 2023Review
- Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer.Frontiers in immunology · 2023Review
- The current status and future prospects for molecular imaging-guided precision surgery.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- Translating Molecules into Imaging-The Development of New PET Tracers for Patients with Melanoma.Diagnostics (Basel, Switzerland) · 2022Review
- A Pilot Study of Radiomics Models Combining Multi-Probe and Multi-Modality Images ofFrontiers in oncology · 2022Article
- Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors.Frontiers in oncology · 2022Review
- Negative Correlation BetweenFrontiers in endocrinology · 2022Article
- Molecular Imaging of Angiogenesis in Oncology: Current Preclinical and Clinical Status.International journal of molecular sciences · 2021Review
- Review
- Peptide-Based Strategies for Targeted Tumor Treatment and Imaging.Pharmaceutics · 2021Review
- Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer.OncoTargets and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this study was to explore the benefit of
methodsSeventy-two patients with NSCLC (37 cases of adenocarcinoma and 35 cases of squamous carcinoma) were enrolled to receive
resultsSignificant differences in ATV and TLA were observed among T1, T2, T3 and T4 cases (ATV, P=0.000; TLA, P=0.000). ATV and TLA also differed significantly among cases of clinical stage I, II, III and IV (ATV, P=0.002; TLA, P=0.011). However, no significant differences in any values were observed between stage III and IV NSCLC cases (SUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.